Intraarticular injection of heparin‐binding insulin‐like growth factor 1 sustains delivery of insulin‐like growth factor 1 to cartilage through binding to chondroitin sulfate

Abstract

Objective. Insulin-like growth factor 1 (IGF-1) stimulates cartilage repair but is not a practical therapy due to its short half-life. We have previously modified IGF-1 by adding a heparin-binding domain and have shown that this fusion protein (HB-IGF-1) stimulates sustained proteoglycan synthesis in cartilage. This study was undertaken to examine the mechanism by which HB-IGF-1 is retained in cartilage and to test whether HB-IGF-1 provides sustained growth factor delivery to cartilage in vivo and to human cartilage explants.Methods. Retention of HB-IGF-1 and IGF-1 was analyzed by Western blotting. The necessity of heparan sulfate (HS) or chondroitin sulfate (CS) glycosaminoglycans (GAGs) for binding was tested using enzymatic removal and cells with genetic deficiency of HS. Binding affinities of HB-IGF-1 and IGF-1 proteins for isolated GAGs were examined by surface plasmon resonance and enzyme-linked immunosorbent assay.Results. In cartilage explants, chondroitinase treatment decreased binding of HB-IGF-1, whereas heparitinase had no effect. Furthermore, HS was not necessary for HB-IGF-1 retention on cell monolayers. Binding assays showed that HB-IGF-1 bound both CS and HS, whereas IGF-1 did not bind either. After intraarticular injection in rat knees, HB-IGF-1 was retained in articular and meniscal cartilage, but not in tendon, consistent with enhanced delivery to CS-rich cartilage. Finally, HB-IGF-1 was retained in human cartilage explants but IGF-1 was not.Conclusion. Our findings indicate that after intraarticular injection in rats, HB-IGF-1 is specifically retained in cartilage through its high abundance of CS. Modification of growth factors with heparin-binding domains may be a new strategy for sustained and specific local delivery to cartilage.

Sustained intra-cartilage delivery of low dose dexamethasone using a cationic carrier for treatment of post traumatic osteoarthritis

“…Often accompanied by damage to other joint tissues, such injuries lead to PTOA with high incidence. Potential disease-modifying OA drugs (DMOADs), including anti-catabolic glucocorticoids (Grodzinsky et al , 2017; Huebner et al , 2014) and pro-anabolic growth factors (Fortier et al , 2001; Miller et al , 2010), have been identified as being able to reverse or prevent PTOA. However, to date, clinical trials evaluating DMOAD candidates have failed due to systemic toxicity or lack of evidence of sustained benefit and/or effective cartilage targeting (Evans et al , 2014).…”

Growth Factor Delivery Through Self-assembling Peptide Scaffolds

“…A new fusion protein made by adding the heparin-binding domain of heparin-binding EGF to IGF-1 (ie, HB-IGF-1) is amenable to delivery in mature articular cartilage [36,49]. A single dose of HB-IGF-1 resulted in sustained delivery and stimulation of proteoglycan synthesis for at least 8 days.…”

Nanodrugs to target articular cartilage: An emerging platform for osteoarthritis therapy

“…In a previous investigation, the authors found that HpB-IGF-1 was primarily retained in articular cartilage through binding to both ChS of aggrecan, while retaining an high affinity for HS chains of perlecan. 62 This property may be crucial to avoid sequestration of the drug in the territorial and inter-territorial zones and enable the transport to the pericellular zone and successive interaction with chondrocytes.…”